[미국특허]
GABA analog prodrug sustained release oral dosage forms
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/22
A61K-031/27
A61K-009/20
출원번호
US-0309662
(2014-06-19)
등록번호
US-8906412
(2014-12-09)
발명자
/ 주소
Cundy, Kenneth C.
Sastry, Srikonda
Leung, Manshiu
Kadri, Balaji V.
Stach, Paul E.
출원인 / 주소
XenoPort, Inc.
대리인 / 주소
Polsinelli PC
인용정보
피인용 횟수 :
0인용 특허 :
59
초록
Sustained release oral dosage forms of a gabapentin prodrug, 1-{(α-isobutanoyloxyethoxy)carbonylaminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
대표청구항▼
1. A method of treating ethanol withdrawal syndrome, alcohol addiction, or cocaine addiction in a patient, comprising administering to the patient in need of such treatment one or more sustained release oral tablets comprising: (a) 40 wt % to 65 wt % of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminometh
1. A method of treating ethanol withdrawal syndrome, alcohol addiction, or cocaine addiction in a patient, comprising administering to the patient in need of such treatment one or more sustained release oral tablets comprising: (a) 40 wt % to 65 wt % of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid;(b) 1 wt % to 30 wt % of glyceryl behenate; and(c) 30 wt % to 50 wt % of dibasic calcium phosphate;wherein wt % is based on the total dry weight of the dosage form, which one or more tablets:when administered to one or more fasted human patients at a dose of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid ranging from 1100 mg to 1300 mg provides a gabapentin plasma concentration profile characterized by a Cmax ranging from 3 μg/mL to 6 μg/mL, a Tmax ranging from 4 hours to 7 hours, and an AUC ranging from 30 μg·hr/mL to 70 μg·hr/mL; orwhen administered to one or more fed human patients at a dose of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid ranging from 1100 mg to 1300 mg provides a gabapentin plasma concentration profile characterized by a Cmax ranging from 5 μg/mL to 8 μg/mL, a Tmax ranging from 6 hours to 11 hours, and an AUC ranging from 60 μg·hr/mL to 110 μg·hr/mL. 2. The method of claim 1, wherein the one or more tablets comprise an amount of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid of about 600 mg. 3. The method of claim 1, wherein the one or more tablets comprise an amount of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid ranging from 300 mg to 700 mg. 4. The method of claim 1, wherein the 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid is in a crystalline form. 5. The method of claim 1, wherein each said tablet comprises one or more pharmaceutically acceptable excipients selected from diluents, lubricants, anti-adherents, glidants, surfactants, disintegrants, and combinations of any of the foregoing. 6. The method of claim 5, wherein the diluent is microcrystalline cellulose. 7. The method of claim 1, wherein the tablets are administered in a dose twice per day. 8. The method of claim 1, comprising a coating. 9. The method of claim 1, which when the one or more tablets are administered to the one or more fasted human patients at a dose of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid ranging from 1100 mg to 1300 mg provides a gabapentin plasma concentration profile characterized by a Cmax ranging from 3 μg/mL to 6 μg/mL, a Tmax ranging from 4 hours to 7 hours, and an AUC ranging from 30 μg·hr/mL to 70 μg·hr/mL; andwhen the one or more tablets are administered to the one or more fed human patients at a dose of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid ranging from 1100 mg to 1300 mg provides a gabapentin plasma concentration profile characterized by a Cmax ranging from 5 μg/mL to 8 μg/mL, a Tmax ranging from 6 hours to 11 hours, and an AUC ranging from 60 μg·hr/mL to 110 μg·hr/mL. 10. The method of claim 1, which when the one or more tablets are administered to a population of said fasted human patients at a dose of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid ranging from a 1100 mg to 1300 mg provides a gabapentin plasma concentration profile characterized by a mean Cmax ranging from 3 μg/mL to 6 μg/mL, a mean Tmax ranging from 4 hours to 7 hours, and a mean AUC ranging from 30 μg·hr/mL to 70 μg·hr/mL; andwhen the one or more tablets are administered to a population of said fed human patients at a dose of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid ranging from 1100 mg to 1300 mg provides a gabapentin plasma concentration profile characterized by a mean Cmax ranging from 5 μg/mL to 8 μg/mL, a mean Tmax ranging from 6 hours to 11 hours, and a mean AUC ranging from 60 μg·hr/mL to 110 μg·hr/mL. 11. The method of claim 1, wherein: the one or more fasted human patients do not eat any food from 10 hours prior to administering the dose until 4 hours after dosing, drink 250 mL of water 2 hours and 1 hour prior to dosing and 250 mL of water a 2 hours after dosing, eat a lunch 4 hours after dosing, and eat a dinner 10 hours after dosing; andthe one or more fed human patients begin eating a test meal 30 minutes prior to administering the dose and complete eating the test meal 5 minutes prior to administering the dose, eat a lunch 4 hours after dosing, and eat a dinner 10 hours after dosing, wherein the test meal comprises 1000 total calories of which 500 calories comprise fat calories. 12. The method of claim 1, wherein alcohol addiction is treated. 13. A method of treating ethanol withdrawal syndrome, alcohol addiction, or cocaine addiction in a patient, comprising administering to the patient in need of such treatment a sustained release oral tablet comprising: (a) 40 wt % to 65 wt % of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid;(b) 1 wt % to 30 wt % of glyceryl behenate; and(c) 30 wt % to 50 wt % of dibasic calcium phosphate;wherein wt % is based on the total dry weight of the tablet, which tablet when placed in 10 mM monobasic potassium phosphate buffer and 1% (wt/volume) sodium lauryl sulfate at pH 7.4 and 37° C. agitated at 50 rpm (USP, Type II), releases 20% of the 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid after 2 hours, 50% after 5 hours, and 80% after 8 hours. 14. The method of claim 13, the tablet comprising an amount of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid ranging from 300 mg to 700 mg. 15. The method according to claim 13, the tablet comprising: 5 wt % to 20 wt % of microcrystalline cellulose. 16. The method of claim 13, the tablet comprising an amount of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid of about 600 mg. 17. The method of claim 13, wherein the dosing comprises frequency of twice per day. 18. The method of claim 13, wherein alcohol addiction is treated. 19. A method of treating ethanol withdrawal syndrome, alcohol addiction, or cocaine addiction in a patient, comprising administering to the patient in need of such treatment a sustained release oral tablet, comprising: 45.8 wt % 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid;39.56 wt % dibasic calcium phosphate;4.58 wt % glyceryl behenate;6.11 wt % talc;0.41 wt % colloidal silicon dioxide;1.84 wt % sodium lauryl sulfate; and1.69 wt % magnesium stearate. 20. The method of claim 19, the tablet comprising 300 mg to 700 mg 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid. 21. The method of claim 19, comprising dosing at a frequency of twice per day. 22. The method of claim 19, the tablet comprising 600 mg 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid. 23. The method of claim 19, wherein alcohol addiction is treated.
Alexander Jose (Lawrence KS), (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs.
Borchardt Ronald T. (Lawrence KS) Siahaan Teruna (Lawrence KS) Gangwar Sanjeev (Lawrence KS) Stella Valentino J. (Lawrence KS) Wang Binghe (Norman OK), Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability.
Urquhart John (Palo Alto CA) Theeuwes Felix (Los Altos CA), Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use.
Ayer Atul D. (Palo Alto CA) Swanson David R. (Palo Alto CA) Kuczynski Anthony L. (Palo Alto CA), Dosage form for treating cardiovascular diseases comprising isradipine.
Bueno Lionel,FRX ; Chovet Maria,FRX ; Diop Laurent,FRX ; Guglietta Antonio ; Little Hilary J.,GBX ; Rafferty Michael Francis ; Ren Jiayuan ; Taylor ; Jr. Charles Price ; Watson William P.,GBX, GABA analogs to prevent and treat gastrointestinal damage.
Silverman Richard B. (Morton Grove IL) Andruszkiewicz Ryszard (Sopot PLX) Yuen Po-Wai (Ann Arbor MI) Sobieray Denis M. (Holland MI) Franklin Lloyd C. (Hamilton MI) Schwindt Mark A. (Holland MI), GABA and L-glutamic acid analogs for antiseizure treatment.
Silverman Richard B. ; Andruszkiewicz Ryszard,PLX ; Yuen Po-Wai ; Sobieray Denis Martin ; Franklin Lloyd Charles ; Schwindt Mark Alan, GABA and L-glutamic acid analogs for antiseizure treatment.
Silverman Richard B. ; Andruszkiewicz Ryszard,PLX ; Yuen Po-Wai ; Sobieray Denis Martin ; Franklin Lloyd Charles ; Schwindt Mark Alan, GABA and L-glutamic acid analogs for antiseizure treatment.
Grosswald Ralph R. (Fairfield IA) Anderson Jeffory B. (Springville UT) Andrew Clair S. (Provo UT), Method for the manufacture of pharmaceutical cellulose capsules.
Raillard,Stephen P.; Zhou,Cindy X.; Yao,Fenmei; Manthati,Suresh Kumar; Xiang,Jia Ning; Gallop,Mark A., Methods for synthesis of acyloxyalkyl derivatives of GABA analogs.
Gallop, Mark A.; Xiang, Jia-Ning; Yao, Fenmei; Bhat, Laxminarayan; Zhou, Cindy X., Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof.
Nabil Farah FR; Philippe Barthelemy FR; Joseph Joachim FR, Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.